ArticleUrologic oncology2025
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.
Article in Urologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeImmune checkpoint blockade (ICB) has transformed outcomes for patients with metastatic renal cell carcinoma (mRCC) and has impacted the timing and use of cytoreductive nephrectomy (CN). As ICB responses vary, we evaluated whether radiographic and radiomic biomarkers were associated with clinical and pathological outcomes.
methodsThis retrospective cohort study included ICB-treated mRCC patients without upfront CN. Clinical and treatment data were collected, and time to next therapy (TTNT) and overall survival (OS) were estimated using Kaplan-Meier analysis. Univariable regression analyses were performed to correlate extracted radiomic features with pathologic outcomes from patients who underwent delayed CN.
resultsFrom 2015 to 2022, 60 mRCC patients met inclusion criteria. Among 43 patients with available imaging data, patients with 3-month radiologic response at both primary and metastatic sites had significantly prolonged TTNT and OS compared to those with progressive disease (PD) at both sites (6-month TTNT 95% vs. 0% and 12-month OS 100% vs. 20%). Primary tumor imaging overestimated pathologically confirmed viable tumor by an average of 622 cm
conclusionResponse patterns in primary and metastatic tumor sites are associated with ICB outcomes. Radiomic features extracted from raw imaging provide an improved surrogate for estimating tumor viability. Efforts to optimize and integrate radiomic data for treatment decision-making are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.